Versantis

Versantis is a spin-off from ETH Zurich, Switzerland, developing a versatile antidote, capable of removing diverse toxic agents from the organism. Today, hospitals have no measure to deal with the acute form of cirrhosis. Using known and safe substances, the ETH spin-off has developed micro-capsules that trap ammonia and other toxins inside them. They will be applied in a procedure that these patients undergo in the hospital anyway. Versants was acquired by GENFIT in 2022.
Versantis logo colour
Vincent Forster about Verve Ventures
Verve Ventures is building a strong portfolio, team and expertise in life sciences. Nevertheless, their strongest impact on our success was their support in all organizational aspects of our company, from HR to Board management, marketing, exit strategies and finances.
Founders / Management Vincent Forster, Meriam Kabbaj
Sectors Health Tech, Pharma, Drugs
Located in Switzerland
Co-Investors Swisscanto, Esperante Ventures, Redalpine, healthEquity, ZKB
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.